Table 2.
Drug used | Study group N = 29 | Reference group N = 70 | All patients N = 820 |
---|---|---|---|
IMiDs: Thal/Len/Pom | 0/2/2 | 0/4/3 | 9/42/8 |
Bortezomib | 9 | 21 | 51 |
Carfilzomib | 3 | 3 | 9 |
TKIs | 3 | 13 | 35 |
Rituximab | 10 | 26 | 52 |
Total | 29 | 70 | 206 |
IMiDs immunomodulators, Thal thalidomide, Len lenalidomide, Pom pomalidomide, TKIs tyrosine kinase inhibitors